Arca Biopharma | ABIO - Gross Profit On Sales


Arca Biopharma reported 0 in Gross Profit on Sales for its fiscal quarter ending in March of 2025.





Gross Profit On Sales Change Date
Amgen USD 6.48B 307M Sep/2025
Arca Biopharma 0 0 Mar/2025
Biogen USD 1.65B 34.6M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Capricor Therapeutics 11.13M 8.87M Dec/2024
Cipla INR 41.64B 6.31B Dec/2025
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 63.8M 63.56M Dec/2025
CSL USD 4.46B 2.71B Dec/2025
Cytokinetics USD 17.76M 15.82M Dec/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Grifols EUR 766.49M 39.74M Dec/2024
Laboratory Of America USD 993.2M 31.9M Dec/2025
Myriad Genetics USD 146.8M 3M Dec/2025
Otsuka Holdings JPY 456.25B 1.16B Mar/2026
Pfizer USD 3.54B 7.61B Sep/2025
United Therapeutics USD 315.5M 286.6M Dec/2025